文献速递关节外科骨质疏松与代谢性骨病

成骨细胞疗法能否改善股骨头坏死骨折前预后?随机对照试验

Did Osteoblastic Cell Therapy Improve the Prognosis of Pre-fracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial.
PubMed 文献 · Clin Orthop Relat Res · 2020-01-01

36个月随访显示两组在进展至ARCO III期、疼痛改善、THA率及不良事件方面均无临床重要差异。

要点

  • 成骨细胞疗法未显著降低骨折进展风险(22% vs 46%,HR 0.47,P=0.15)。
  • 两组VAS疼痛评分、WOMAC及Lequesne指数均无临床重要差异。
  • THA率成骨细胞组15% vs BMAC组35%,差异无统计学意义(P=0.09)。

核心结论

  • 在骨折前股骨头坏死患者中,成骨细胞疗法相比BMAC未显示获益。
  • 两组副作用不常见且总体轻微。
  • 该疗法在更大规模研究证实疗效前不推荐常规使用。

研究设计与样本

  • 成骨细胞组30例,BMAC组26例,均行髓芯减压联合相应植入。
  • 主要终点为进展至ARCO III期或更高且VAS疼痛改善≥1cm的复合应答。
  • 随访36个月,疗效分析采用as-treated,不良事件采用intention-to-treat。

主要发现

  • 36个月时进展至ARCO III期或更高:BMAC组46%(12/26) vs 成骨细胞组22%(6/27),HR 0.47(95%CI 0.17-1.31),P=0.15。
  • VAS疼痛评分、WOMAC及Lequesne指数均无临床重要差异。
  • 36个月THA率:成骨细胞组15%(4/27) vs BMAC组35%(9/26),P=0.09。
  • 两组主要不良事件频率无差异。

关键数值与推荐

  • 主要终点定义为无进展至ARCO III期或更高且VAS疼痛改善≥1cm(10cm VAS)。
  • 进展至骨折的HR为0.47(95%CI 0.17-1.31),P=0.15。
  • THA率比较P=0.09。

临床怎么用

  • 对于ARCO I-II期非创伤性ONFH,成骨细胞疗法不应作为常规推荐。
  • 髓芯减压联合BMAC仍是可选方案,但需个体化评估。
  • 成骨细胞疗法的疗效需更大规模多中心RCT进一步验证。

局限性

  • 仅24%符合条件患者同意参与,存在选择偏倚可能。
  • 疗效分析采用as-treated而非intention-to-treat。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with nontraumatic osteonecrosis of the femoral head (ONFH), implantation of bone marrow aspirate concentrate (BMAC) could delay the progression of osteonecrosis and improve symptoms in pre-fracture ONFH. However, the BMAC content, especially in osteoblastic stem cells, could have an important individual variability. An autologous osteoblastic cell product could improve the effect of such cell-based therapy. QUESTIONS/PURPOSES: (1) Does autologous osteoblastic cell therapy decrease the likelihood of progression to subchondral fracture with or without early collapse corresponding to Association Research Circulation Osseous (ARCO) classification Stage III or higher, and provide a clinically important pain improvement compared with BMAC treatment alone? (2) Were patients treated with osteoblastic cell therapy less likely to undergo subsequent THA? (3) What proportion of patients in the treatment and control groups experienced adverse events after surgery? METHODS: Between 2004 and 2011, we treated 279 patients for Stage I to II hip osteonecrosis (ON) with surgery. During that time, our general indications for surgery in this setting included non-fracture ON lesions. To be eligible for this randomized, single-blind trial, patients needed to have an ONFH Stage I or II; we excluded those with traumatic ONFH, hemoglobinopathies and positive serology for hepatitis B, C or HIV. Of those treated surgically for this diagnosis during the study period, 24% (67) agreed to participate in this randomized trial. Hips with pre-fracture ONFH were randomly treated with a core decompression procedure associated with either implantation of a BMAC (BMAC group; n = 26) or osteoblastic cell (osteoblastic cell group; n = 30). The groups were not different in terms of clinical and imaging characteristics. The primary study outcome was treatment response, defined as the absence of progression to subchondral fracture stage (ARCO stage III or higher) plus a clinically important pain improvement defined as 1 cm on a 10-cm VAS. The secondary endpoint of interest was the frequency in each group of subsequent THA and the frequency of adverse events. The follow-up duration was 36 months. We used an as-treated analysis (rather than intention-to-treat) for our efficacy endpoint, and an intention-to-treat analysis for adverse events. Overall, 26 of 26 patients in the BMAC group and 27 of 30 in the osteoblastic cell group completed the trial. RESULTS: At 36 months, no clinically important differences were found in any study endpoint. There was no difference in the proportion of patients who had progressed to fracture (ARCO stage III or higher; 46% of the BMAC hips [12 of 26] versus 22% in the hips with osteoblastic cells [six of 27], hazard ratio, 0.47 [95% CI 0.17 to 1.31]; p = 0.15). There was no clinically important difference in VAS pain scores. No differences were found for either the WOMAC or the Lequesne indexes. With the numbers available, there was no difference in the proportion of patients in the groups who underwent THA at 36 months 15% (four of 27) with osteoblastic cells versus 35% (nine of 26) with BMAC; p = 0.09 With the numbers available, we found no differences between the treatment and control groups in terms of the frequencies of major adverse events. CONCLUSIONS: We found no benefit to osteoblastic cells over BMAC in patients with pre-collapse ONFH; side effects were uncommon and generally mild in both groups. This study could be used as pilot data to help determine sample sizes for larger (presumably multicenter) randomized controlled trials. However, this novel treatment cannot be recommended in routine practice until future, larger studies demonstrate efficacy. LEVEL OF EVIDENCE: Level II, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Hauzeur JP, Lechanteur C, Baudoux E, et al. Did Osteoblastic Cell Therapy Improve the Prognosis of Pre-fracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial. Clin Orthop Relat Res. 2020. PMID: 31899739. doi:10.1097/CORR.0000000000001107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。